Why the study?
Is there an obesity paradox for outcomes in atrial fibrillation patients treated with NOACs versus warfarin?
Is there an obesity paradox for outcomes in atrial fibrillation patients treated with NOACs versus warfarin?
The efficacy and safety benefits of NOACs over warfarin in atrial fibrillation may be significant only for normal weight patients, suggesting an obesity paradox.
Suggests obesity paradox may limit NOAC benefits to normal-weight AF patients; hypothesis-generating and requires prospective validation.
There may be an obesity paradox in atrial fibrillation patients, particularly for all-cause and cardiovascular death outcomes. An obesity paradox was also evident for stroke/systemic embolic event outcome in NOAC trials, with a treatment effect favoring NOACs over warfarin for both efficacy and safety that was significant only for normal weight patients.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: